{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:53:10Z","timestamp":1781650390565,"version":"3.54.5"},"reference-count":51,"publisher":"Norwegian Medical Association","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2014,4,8]]},"DOI":"10.4045\/tidsskr.13.0565","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T09:48:03Z","timestamp":1397123283000},"page":"710-4","source":"Crossref","is-referenced-by-count":4,"title":["Kardiovaskul\u00e6r risikovurdering ved bruk av AD\/HD-medikamenter hos barn"],"prefix":"10.4045","volume":"134","author":[{"given":"Ansgar","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelinn","family":"Br\u00e5tane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Henrik","family":"Odland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-5131","authenticated-orcid":false,"given":"Christina","family":"Brudvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rg","family":"Rosland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asle","family":"Hirth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"Veileder i diagnostikk og behandling av AD\/HD. IS-1244. 2005, revidert 2007. Oslo: Sosial- og helsedirektoratet, 2007."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Lillemoen PK, Kjosavik SR, Hunsk\u00e5r S et al. F\u00f8reskriving av legemiddel mot AD\/HD 2004\u2009\u2013\u200908. Tidsskr Nor Legeforen 2012; 132: 1856\u2009\u2013\u200960. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22986969&dopt=Abstract","DOI":"10.4045\/tidsskr.11.1270"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Brown RT, Amler RW, Freeman WS et al. Treatment of attention-deficit\/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115: e749\u2009\u2013\u200957. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15930203&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1542\/peds.2004-2560","DOI":"10.1542\/peds.2004-2560"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16549404&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMp068049","DOI":"10.1056\/NEJMp068049"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Vetter VL, Elia J, Erickson C et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit\/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407\u2009\u2013\u200923. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18427125&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/CIRCULATIONAHA.107.189473","DOI":"10.1161\/CIRCULATIONAHA.107.189473"},{"key":"ref=6","unstructured":"FDA. U.S. Food and Drug Administration. Drug. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm107918.htm (1.5.2013)."},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Perrin JM, Friedman RA, Knilans TK et al. Cardiovascular monitoring and stimulant drugs for attention-deficit\/hyperactivity disorder. Pediatrics 2008; 122: 451\u2009\u2013\u20093. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18676566&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1542\/peds.2008-1573","DOI":"10.1542\/peds.2008-1573"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073\u2009\u2013\u200986. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10591283&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/archpsyc.56.12.1073","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776\u2009\u2013\u200984. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12108801&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/00004583-200207000-00008","DOI":"10.1097\/00004583-200207000-00008"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Wernicke JF, Faries D, Girod D et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729\u2009\u2013\u200940. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12862507&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00002018-200326100-00006","DOI":"10.2165\/00002018-200326100-00006"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Findling RL, Biederman J, Wilens TE et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005; 147: 348\u2009\u2013\u200954. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16182674&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jpeds.2005.03.014","DOI":"10.1016\/j.jpeds.2005.03.014"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr 2005; 10 (suppl 15): 22\u2009\u2013\u200930. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17151573&dopt=Abstract","DOI":"10.1017\/S1092852900014115"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit\/hyperactivity disorder. Biol Psychiatry 2007; 61: 706\u2009\u2013\u200912. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16899230&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.biopsych.2006.05.002","DOI":"10.1016\/j.biopsych.2006.05.002"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Vitiello B, Elliott GR, Swanson JM et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 2012; 169: 167\u2009\u2013\u200977. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21890793&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1176\/appi.ajp.2011.10111705","DOI":"10.1176\/appi.ajp.2011.10111705"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Hammerness PG, Perrin JM, Shelley-Abrahamson R et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit\/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011; 50: 978\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21961773&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jaac.2011.07.018","DOI":"10.1016\/j.jaac.2011.07.018"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Winterstein AG, Gerhard T, Shuster J et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit\/hyperactivity disorder. Pediatrics 2007; 120: e1494\u2009\u2013\u2009501. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18055666&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1542\/peds.2007-0675","DOI":"10.1542\/peds.2007-0675"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Michelson D, Read HA, Ruff DD et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17242628&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/01.chi.0000246056.83791.b6","DOI":"10.1097\/01.chi.0000246056.83791.b6"},{"key":"ref=18","unstructured":"Sikkerhetsinformasjon Eli Lilly. Oslo: Statens legemiddelverk, 2011. www.legemiddelverket.no\/Bivirkninger\/helsepersonell-brev\/helsepersonell-brev_utsendt\/Documents\/2011\/Strattera_DHCP_letter_incl.attachments_06.12.2011.pdf (6.12.2011)."},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Cooney MT, Vartiainen E, Laatikainen T et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010; 159: 612\u2009\u2013\u20099.","DOI":"10.1016\/j.ahj.2009.12.029"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Biederman J, Mick E, Surman C et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder. Biol Psychiatry 2006; 59: 829\u2009\u2013\u200935. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16373066&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.biopsych.2005.09.011","DOI":"10.1016\/j.biopsych.2005.09.011"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Spencer T, Biederman J, Wilens T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit\/hyperactivity disorder. Biol Psychiatry 2005; 57: 456\u2009\u2013\u200963. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15737659&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.biopsych.2004.11.043","DOI":"10.1016\/j.biopsych.2004.11.043"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Stiefel G, Besag FMC. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010; 33: 821\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20812768&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/11536380-000000000-00000","DOI":"10.2165\/11536380-000000000-00000"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23B-25B. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8256751&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/0002-9149(93)90036-C","DOI":"10.1016\/0002-9149(93)90036-C"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004; 9 (suppl 1): S85\u2009\u2013\u200997. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15378133&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177\/107424840400900107","DOI":"10.1177\/107424840400900107"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Schwartz PJ, Stramba-Badiale M, Segantini A et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1709\u2009\u2013\u200914. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9624190&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJM199806113382401","DOI":"10.1056\/NEJM199806113382401"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Napolitano C, Bloise R, Memmi M et al. Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT). Eur J Hum Genet 2014; 22. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23549275&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/ejhg.2013.55","DOI":"10.1038\/ejhg.2013.55"},{"key":"ref=27","unstructured":"Wikstr\u00f6m G, Kvidal P, Hagstr\u00f6m E. Livshotande hj\u00e4rtsvikt av ADHD medisinering. Fem patientfall beskrivs. L\u00e4kartidningen 2012; 109: 2016\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23240309&dopt=Abstract"},{"key":"ref=28","unstructured":"Food and drug administration. FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108849.htm (1.5.2013)."},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Schelleman H, Bilker WB, Strom BL et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127: 1102\u2009\u2013\u200910. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21576311&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1542\/peds.2010-3371","DOI":"10.1542\/peds.2010-3371"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Cooper WO, Habel LA, Sox CM et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365: 1896\u2009\u2013\u2009904. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22043968&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1110212","DOI":"10.1056\/NEJMoa1110212"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Habel LA, Cooper WO, Sox CM et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306: 2673\u2009\u2013\u200983. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22161946&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jama.2011.1830","DOI":"10.1001\/jama.2011.1830"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Winterstein AG, Gerhard T, Kubilis P et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345: e4627. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22809800&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/bmj.e4627","DOI":"10.1136\/bmj.e4627"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Olfson M, Huang C, Gerhard T et al. Stimulants and cardiovascular events in youth with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51: 147\u2009\u2013\u200956. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22265361&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jaac.2011.11.008","DOI":"10.1016\/j.jaac.2011.11.008"},{"key":"ref=34","unstructured":"FDA. ADHD medications and risk of stroke in young and middle-aged adults. www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM279877.pdf. (1.5.2013)."},{"key":"ref=35","unstructured":"American Academy of Pediatrics\/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD. Circulation. http:\/\/newsroom.heart.org\/news\/american-academy-of-pediatrics-218228 (1.5.2013)."},{"key":"ref=36","unstructured":"AD\/HD \u2013 Nasjonal faglig retningslinje for utredning, behandling og oppf\u00f8lging. http:\/\/helsedirektoratet.no\/Om\/hoyringar\/Documents\/ADHD\/Retningslinje%2013%20februar%202013.pdf (1.5.2013)."},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Thomas PE, Carlo WF, Decker JA et al. Impact of the American Heart Association scientific statement on screening electrocardiograms and stimulant medications. Arch Pediatr Adolesc Med 2011; 165: 166\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21300657&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/archpediatrics.2010.278","DOI":"10.1001\/archpediatrics.2010.278"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984; 59: 971\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6541894&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/adc.59.10.971","DOI":"10.1136\/adc.59.10.971"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Dougherty KR, Friedman RA, Link MS et al. Prediction and prevention of sudden death in young populations: the role of ECG screening. J Interv Card Electrophysiol 2013; 36: 167\u2009\u2013\u200975. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23179925&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s10840-012-9755-5","DOI":"10.1007\/s10840-012-9755-5"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Mahle WT, Hebson C, Strieper MJ. Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol 2009; 104: 1296\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19840580&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.amjcard.2009.06.052","DOI":"10.1016\/j.amjcard.2009.06.052"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Pelliccia A, Maron BJ, Culasso F et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000; 102: 278\u2009\u2013\u200984. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10899089&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/01.CIR.102.3.278","DOI":"10.1161\/01.CIR.102.3.278"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Weiner RB, Hutter AM, Wang F et al. Performance of the 2010 European Society of Cardiology criteria for ECG interpretation in athletes. Heart 2011; 97: 1573\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21602522&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/hrt.2011.227330","DOI":"10.1136\/hrt.2011.227330"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Asif IM, Rao AL, Drezner JA. Sudden cardiac death in young athletes: what is the role of screening? Curr Opin Cardiol 2013; 28: 55\u2009\u2013\u200962. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23196775&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/HCO.0b013e32835b0ab9","DOI":"10.1097\/HCO.0b013e32835b0ab9"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Corrado D, Basso C, Pavei A et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006; 296: 1593\u2009\u2013\u2009601. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17018804&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001\/jama.296.13.1593","DOI":"10.1001\/jama.296.13.1593"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Hamilton RM, Rosenthal E, Hulpke-Wette M et al. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young 2012; 22: 63\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21771383&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1017\/S1047951111000928","DOI":"10.1017\/S1047951111000928"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Graham J, Banaschewski T, Buitelaar J et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011; 20: 17\u2009\u2013\u200937. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21042924&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00787-010-0140-6","DOI":"10.1007\/s00787-010-0140-6"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics 1996; 98: 649\u2009\u2013\u200958. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8885941&dopt=Abstract","DOI":"10.1542\/peds.98.4.649"},{"key":"ref=48","unstructured":"USDA\/ARS Children\u2019s Nutrition Research Center. Houston, Texas. Age-based Pediatric Blood Pressure Reference Charts. www.bcm.edu\/bodycomplab\/Flashapps\/BPVAgeChartpage.html (1.5.2013)."},{"key":"ref=49","unstructured":"Hamilton R, Gray C, B\u00e9langer SA et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry 2009; 18: 349\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19881947&dopt=Abstract"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Shillingford AJ, Glanzman MM, Ittenbach RF et al. Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 2008; 121: e759\u2009\u2013\u200967. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18381503&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1542\/peds.2007-1066","DOI":"10.1542\/peds.2007-1066"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Batra AS, Alexander ME, Silka MJ. Attention-deficit\/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason. Pediatr Cardiol 2012; 33: 394\u2009\u2013\u2009401. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22298228&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00246-012-0162-6","DOI":"10.1007\/s00246-012-0162-6"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:03:05Z","timestamp":1781647385000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2014\/04\/oversiktsartikkel\/kardiovaskulaer-risikovurdering-ved-bruk-av-adhd-medikamenter-hos-barn"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,8]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,4,8]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.13.0565","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,8]]}}}